infect
virus
promptli
recogn
host
innat
pattern
recognit
receptor
prr
includ
tolllik
receptor
tlr
rigilik
receptor
rlr
nodlik
receptor
ctype
lectin
result
product
type
interferon
ifn
proinflammatori
cytokin
chemokin
orchestr
elimin
pathogen
essenti
role
prrmediat
innat
immun
respons
defend
microorgan
infect
extens
demonstr
vivo
murin
model
knockout
gene
encod
either
specif
prr
key
signal
compon
review
howev
like
adapt
immun
innat
immun
respons
also
detriment
host
inde
mani
occas
viral
replic
overwhelm
product
proinflammatori
cytokin
caus
sever
inflamm
tissu
damag
blood
vessel
leakag
occasion
permeabil
blood
brain
barrier
lead
penetr
infect
central
nervou
system
virus
addit
vital
role
prr
defend
viru
infect
pharmacolog
activ
prrmediat
innat
host
respons
extens
explor
broadspectrum
antivir
approach
howev
systemat
administr
prr
agonist
dose
necessari
achiev
antivir
effect
usual
associ
signific
advers
reaction
due
activ
widespectrum
cellular
respons
massiv
product
proinflammatori
cytokin
tlr
rlr
two
major
type
prr
recogn
viru
infect
induc
innat
immun
respons
interestingli
induct
type
ifn
primari
antivir
cytokin
proinflammatori
cytokin
upon
activ
tlr
rlr
control
multipl
overlap
distinct
signal
transduct
pathway
review
activ
nuclear
factor
kappalightchainenhanc
activ
b
cell
distinct
mitogenactiv
protein
kinas
mapk
pathway
critic
product
mani
proinflammatori
cytokin
chemokin
activ
interferon
regulatori
factor
pathway
requir
induct
type
ifn
well
group
antivir
protein
guanyl
bind
protein
zinc
finger
antivir
protein
addit
although
three
map
kinas
erk
jnk
activ
tlr
rlr
agonist
viral
infect
three
mapk
demonstr
play
distinct
role
regul
express
type
ifn
proinflammatori
gene
exampl
shown
recent
erk
activ
requir
chemokin
product
murin
dendrit
cell
wherea
jnk
activ
neg
regulatori
effect
chemokin
product
therefor
possibl
pharmacolog
modul
viru
andor
prragonistinduc
innat
immun
respons
target
distinct
signal
transduct
pathway
select
enhanc
antivir
respons
allevi
detriment
inflammatori
respons
conceiv
therapi
effect
broad
spectrum
viru
infect
either
alon
combin
prr
agonist
order
discov
compound
expect
pharmacolog
properti
set
establish
report
cell
line
high
throughput
screen
small
molecul
select
enhanc
ligandinduc
gene
express
affect
activ
central
player
induct
proinflammatori
cytokin
play
less
promin
role
type
ifn
gene
express
initi
high
throughput
screen
campaign
thu
far
identifi
compound
ro
select
enhanc
rlr
ligandinduc
gene
express
antivir
respons
like
via
activ
mapk
pathway
pathway
result
thu
prove
concept
pharmacolog
modul
agonistinduc
innat
immun
respons
viabl
antivir
therapeut
strategi
type
ifn
primari
antivir
cytokin
induc
prr
agonistactiv
innat
immun
respons
wherea
key
transcript
factor
induct
proinflammatori
cytokin
chemokin
play
less
import
role
gene
activ
first
set
establish
cellbas
assay
suitabl
high
throughput
screen
compound
select
enhanc
agonistinduc
type
ifn
product
without
enhanc
activ
two
invivogen
deriv
stabl
report
cell
line
express
firefli
luciferas
control
human
promot
design
artifici
promot
contain
consensu
bind
site
clontech
design
establish
shown
fig
poli
c
treatment
report
cell
line
induc
luciferas
express
concentr
depend
manner
expect
poli
c
treatment
cell
line
without
fail
induc
luciferas
express
data
shown
moreov
shown
fig
b
poli
cinduc
luciferas
express
dosedepend
inhibit
chloroquin
lysosom
acidif
inhibitor
inhibitor
iv
inhibitor
cell
inhibitor
phosphoatidylinositol
requir
activ
inhibit
poli
cinduc
luciferas
express
cell
fig
result
thu
valid
luciferas
express
cell
control
function
promot
respons
element
respect
screen
small
molecul
librari
pharmacolog
activ
compound
lopac
obtain
sigma
abl
identifi
compound
ro
fig
affect
neither
promot
activ
significantli
enhanc
poli
cinduc
promot
activ
inhibit
activ
dosedepend
manner
fig
c
enhanc
promot
activ
statist
signific
dose
rang
inhibit
activ
statist
signific
highest
dose
test
cytotox
observ
concentr
ro
mtt
assay
fig
observ
increas
promot
activ
caus
ro
may
due
enhanc
poli
c
activ
altern
due
disrupt
feedback
inhibit
pathway
order
distinguish
two
possibl
timecours
studi
perform
shown
fig
presenc
ro
increas
peak
level
promot
activ
h
poli
c
treatment
promot
activ
declin
similar
kinet
sinc
peak
time
absenc
presenc
ro
consist
result
shown
fig
c
ro
inhibit
activ
fig
result
thu
impli
ro
like
target
molecular
event
activ
neg
feedback
regul
signal
transduct
pathway
prolong
activ
promot
differenti
regul
ro
activ
promot
induc
poli
c
suggest
compound
modul
signal
transduct
target
ligand
rna
agreement
notion
observ
timeofaddit
experi
ro
abl
effici
enhanc
poli
c
activ
promot
ad
h
time
even
h
addit
poli
c
cultur
media
fig
howev
compound
enhanc
poli
cinduc
promot
activ
cell
pretreat
compound
h
follow
treatment
poli
c
absenc
ro
addit
h
treatment
schedul
result
indic
ro
effect
promot
activ
absenc
ligand
suggest
compound
pharmacolog
activ
virallyinfect
uninfect
cell
confirm
observ
made
report
cell
line
measur
effect
ro
ligandinduc
endogen
chemokin
express
human
monocyt
cell
line
cell
consist
result
obtain
report
assay
treatment
cell
ro
alon
fail
induc
gene
express
compound
significantli
increas
induct
presenc
poli
c
cell
fig
secret
typei
ifn
cell
fig
secret
fig
downstream
signal
pathway
lead
activ
inflammatori
cytokin
gene
express
larg
share
cytoplasm
rlr
set
test
whether
ro
could
also
enhanc
activ
promot
elicit
cytoplasm
deliveri
doubl
strand
rna
activ
rigi
cell
express
shown
fig
inhibitor
essenti
activ
dosedepend
inhibit
promoterdriven
luciferas
express
fig
ro
significantli
enhanc
promot
activ
cytoplasmicdeliv
poli
c
fig
henc
result
impli
ro
like
target
share
induct
pathway
activ
rlr
investig
whether
enhanc
respons
ro
could
result
enhanc
antivir
respons
cell
mock
treat
treat
poli
c
ro
alon
combin
h
cell
challeng
vesicular
stomat
viru
vsv
viru
yield
determin
plaqu
assay
agreement
result
present
treatment
cell
ro
alon
demonstr
detect
antivir
effect
howev
viru
yield
significantli
reduc
cell
receiv
combin
treatment
treat
poli
c
alon
fig
similar
result
obtain
encephalomyocardit
viru
emcv
infect
data
shown
determin
biolog
activ
ro
mapk
pathway
cell
mock
treat
treat
poli
c
ro
alon
combin
min
level
total
phosphoryl
erk
jnk
determin
immunoblot
assay
shown
fig
poli
c
treatment
abl
activ
three
mapk
pathway
test
interestingli
treatment
cell
ro
alon
abl
effici
activ
makp
lesser
extent
erk
jnk
pathway
furthermor
ro
also
abl
enhanc
activ
three
mapk
poli
c
determin
role
three
mapk
poli
cinduc
promot
activ
inhibitor
three
mapk
appli
poli
c
treat
cell
shown
fig
inhibitor
erk
jnk
inhibitor
significantli
inhibit
poli
cinduc
promot
activ
observ
conjunct
fact
ro
slightli
suppress
poli
cinduc
activ
fig
affect
poli
cinduc
nuclear
transloc
activ
gene
express
data
shown
impli
activ
mapk
pathway
like
respons
observ
enhanc
express
antivir
respons
ro
tlr
rlr
princip
pattern
recognit
receptor
sens
viru
infect
mount
defens
activ
innat
immun
respons
review
howev
also
observ
mani
circumst
tlr
andor
rlrmediat
innat
immun
respons
play
critic
role
viral
pathogenesi
exampl
pneumonia
caus
influenza
viru
sarscoronaviru
infect
hemorrhag
fever
caus
dengu
viru
mani
virus
enceph
caus
west
nile
viru
infect
demonstr
larg
due
detriment
effect
proinflammatori
cytokin
induc
infect
moreov
identif
tlr
rlr
key
pathogen
recognit
receptor
innat
immun
spark
great
interest
therapeut
manipul
innat
immun
system
tlr
rlr
agonist
develop
treatment
cancer
allergi
viral
infect
adjuv
vaccin
prevent
treat
cancer
infecti
diseas
despit
tremend
effort
imiquimod
aldara
agonist
approv
us
fda
treatment
papillomavirusinduc
genit
wart
basal
cell
carcinoma
via
topic
use
due
activ
widespectrum
cellular
respons
surpris
systemat
administr
tlr
agonist
dose
necessari
achiev
antivir
antitumor
effect
usual
associ
signific
advers
effect
studi
signal
transduct
pathway
elicit
tlr
rlr
agonist
thu
far
reveal
induct
type
ifn
proinflammatori
cytokin
control
distinct
signal
transduct
pathway
conceiv
pharmacolog
modul
tlr
andor
rlr
signal
transduct
pathway
may
alter
cytokin
profil
induc
prr
agonist
thu
differenti
promot
benefici
innat
immun
respons
limit
detriment
effect
effort
toward
discoveri
molecul
pharmacolog
properti
identifi
ro
compound
origin
report
inhibitor
amyloidbeta
peptid
abeta
assembl
vitro
ro
select
enhanc
agonistinduc
type
ifn
product
human
kidney
epithelia
macrophag
cell
line
fig
promot
activ
chemokin
product
expect
treatment
cell
ro
significantli
enhanc
antivir
activ
poli
c
fig
molecular
pathway
analys
reveal
ro
slightli
suppress
poli
cinduc
activ
appar
alter
agonistinduc
nuclear
transloc
activ
gene
express
data
shown
interestingli
show
treatment
cell
ro
abl
rapidli
activ
mapk
lesser
extent
erk
jnk
although
molecular
target
signal
pathway
lead
activ
mapk
ro
remain
determin
plausibl
ro
activ
mapk
essenti
agonistinduc
gene
express
fig
may
respons
enhanc
respons
iron
ro
enhanc
respons
presenc
agonist
fail
condit
cell
pretreat
compound
h
follow
treatment
poli
c
absenc
addit
h
fig
result
impli
besid
addit
shortliv
cellular
respons
induc
ro
may
also
requir
innat
immun
enhanc
activ
corrobor
work
report
herein
conforti
colleagu
recent
show
vivo
inject
poli
u
agonist
combin
immunochemotherapeut
regimen
abl
inhibit
posit
breast
tumor
growth
interestingli
agonist
elicit
product
rang
chemokin
tumor
cell
blockad
improv
efficaci
immunochemotherapi
blockad
abolish
benefici
effect
therefor
work
show
oppos
innat
immun
respons
mediat
chemokin
pharmacolog
modul
enhanc
anticanc
efficaci
agonist
summari
other
demonstr
pharmacolog
modul
signal
function
downstream
chemokin
andor
cytokin
alter
agonistinduc
innat
immun
respons
enhanc
antivir
anticanc
effect
regardless
whether
ro
deriv
develop
therapeut
agent
enhanc
antivir
respons
agonist
studi
support
concept
pharmacolog
modul
tlr
rlr
signal
transduct
pathway
attract
approach
antivir
drug
develop
cell
cultur
dmem
supplement
fb
mm
lglutamin
gl
sodium
bicarbon
uml
penicillin
streptomycin
cellderiv
stabl
cell
line
express
hatag
purchas
invivogen
cultur
complet
dmem
medium
contain
blasticidin
cell
kind
gift
dr
r
phillip
immunotop
inc
origin
purchas
atcc
cultur
rmpi
medium
contain
fetal
bovin
serum
penicillinstreptomycin
hekblu
cell
invivogen
express
secret
embryon
alkalin
phosphatas
seap
control
promot
cultur
complet
dmem
medium
contain
zeocin
blasticidin
vesicular
stomat
viru
propag
titrat
describ
previous
poli
c
purchas
invivogen
ro
chloroquin
purchas
sigma
cell
signal
inhibitor
iv
purchas
santa
cruz
technolog
cell
cotransfect
plasmid
express
firefli
luciferas
control
human
promot
artifici
promot
contain
four
repetit
consensu
bind
site
clontech
invitrogen
molar
ratio
twentyfour
hour
post
transfect
cell
reseed
densiti
cell
per
dish
diamet
cultur
medium
contain
individu
cell
coloni
pick
day
post
transfect
cell
coloni
demonstr
highest
level
poli
cinduc
luciferas
express
measur
steadyglo
reagent
promega
expand
cell
line
design
respect
order
creat
similar
cell
line
studi
cytoplasm
rigilik
receptormedit
innat
immun
respons
parent
cell
devoid
cotransfect
plasmid
express
firefli
luciferas
control
human
promot
molar
ratio
clone
express
high
level
luciferas
respons
lipofectaminemedi
transfect
poli
c
identifi
design
cell
seed
densiti
cellswel
black
wall
flatbottom
clear
plate
corn
inc
cell
allow
grow
h
treatment
primari
screen
column
plate
mock
treat
treat
poli
c
respect
remain
well
treat
poli
c
compound
librari
pharmacolog
activ
compound
lopac
sigma
concentr
subsatur
concentr
poli
c
use
identifi
posit
neg
modul
agonistinduc
innat
immun
respons
firefli
luciferas
activ
measur
h
dsrna
addit
ad
steadyglo
reagent
promega
follow
luminometri
topcount
perkin
elmer
raw
luciferas
activ
data
librari
compoundtr
well
normal
percentag
activ
rel
cell
treat
poli
c
alon
compound
reduc
increas
luciferas
activ
consid
primari
hit
hit
compound
subject
evalu
cytotox
mtt
assay
promega
confirm
abil
inhibit
enhanc
poli
c
activ
promot
report
assay
describ
expand
rang
concentr
triplic
cell
mock
treat
treat
ro
poli
c
alon
combin
min
lyse
laemmli
buffer
fraction
cell
lysat
separ
sodium
dodecyl
polyacrylamin
gel
electrophoret
transfer
onto
pvdf
membran
biorad
membran
block
pb
contain
nonfat
dri
milk
probe
antibodi
total
phophoryl
erk
jnk
cell
signal
bound
antibodi
reveal
incub
irdy
secondari
antibodi
imag
licor
odyssey
system
licor
biotechnolog
cell
mock
treat
treat
ro
poli
c
alon
combin
total
rna
isol
trizol
invitrogen
cdna
synthes
use
superscript
iii
cdna
synthesi
kit
invitrogen
subject
pcr
amplif
forward
primer
sequenc
revers
primer
sequenc
forward
primer
sequenc
revers
primer
sequenc
use
platinum
taq
polymeras
invitrogen
cell
mock
treat
treat
ro
poli
c
alon
combin
h
cultur
media
harvest
hekblu
cell
invivogen
seed
densiti
cell
per
well
plate
one
day
post
seed
cell
cultur
condit
media
harvest
treat
cell
h
level
seap
cultur
media
determin
quantiblu
assay
invivogen
follow
instruct
manufactur
invivogen
cultur
medium
cell
treat
dose
poli
c
ro
alon
combin
measur
use
human
elisa
kit
invitrogen
follow
manufactur
instruct
cell
seed
plate
densiti
cell
per
well
twentyfour
hour
post
seed
cell
mock
transfect
rna
transfect
poli
c
per
well
lipofectamin
follow
manufactur
direct
invitrogen
mock
treat
treat
ro
h
cell
seed
plate
densiti
cell
per
well
twentyfour
hour
post
seed
cell
either
mock
treat
treat
indic
concentr
poli
c
absenc
presenc
ro
h
cell
infect
vsv
moi
cultur
media
harvest
h
post
infect
viru
yield
determin
plaqu
assay
determin
cell
viabil
mtt
base
assay
perform
sigma
previous
describ
cell
seed
densiti
cell
per
well
plate
one
day
post
seed
cell
mock
treat
treat
serial
dilut
ro
rang
h
dosedepend
absorb
valu
nm
indic
cell
viabil
determin
plot
follow
manufactur
instruct
